Blood markers may reveal chemo response in just weeks
NCT ID NCT02872779
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 74 people with metastatic colorectal cancer starting their first chemotherapy. Researchers took blood samples early in treatment to measure three markers: CEA, circulating tumor DNA, and total cell-free DNA. The goal was to see if early changes in these markers could predict whether the cancer would shrink after 3 months, potentially allowing doctors to adjust treatment much sooner.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a blood test that helps doctors quickly tell if chemotherapy is working, allowing them to switch treatments sooner and avoid unnecessary side effects.
What could go wrong
This is a small, observational study that is not testing a new treatment. The results may not be definitive enough to change standard care, and the blood markers might not reliably predict outcomes in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rouen University Hospital
Rouen, France